Send to:

Choose Destination
See comment in PubMed Commons below
Bioorg Med Chem Lett. 2013 Dec 1;23(23):6363-9. doi: 10.1016/j.bmcl.2013.09.061. Epub 2013 Oct 1.

Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors.

Author information

  • 1Janssen Pharmaceutical Research & Development LLC, Welsh & McKean Roads, Spring House, PA 19477, USA.


Structure-activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7 nM, FMS cell IC50 6.1 nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats.

Copyright © 2013 Elsevier Ltd. All rights reserved.


Anti-inflammatory; Colony-stimulating factor-1 receptor; FMS; Hypocellularity; KIT; Macrophage colony-stimulating factor; Rheumatoid arthritis

[PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Chemical Information

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk